Showing results (201-210 of 279) with videos related to
Sort By:
Pageof 28
Cancer Prevention Research (Philadelphia, Pa.)|May 31, 2024
Multiyear Clinical Outcomes of Cancers Diagnosed Following Detection by a Blood-Based Multicancer Early Detection TestAdam H Buchanan, Anne M Lennon, Omair A Choudhry, et al.Journal for Immunotherapy of Cancer|July 4, 2020
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide aloneJulie N Graff, Tomasz M Beer, Joshi J Alumkal, et al.Nature Communications|January 10, 2019
Publisher Correction: Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.Clinical Genitourinary Cancer|February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical researchMichael J Morris, Ethan M Basch, George Wilding, et al.Nature Communications|November 28, 2018
Interplay between hypoxia and androgen controls a metabolic switch conferring resistance to androgen/AR-targeted therapyHao Geng, Changhui Xue, Janet Mendonca, et al.Plos One|September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRyan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.The Oncologist|May 11, 2026
A Phase I/II Trial of Concurrent Chemo-hormonal Enzalutamide and Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate CancerJulie N Graff, Claire E P Smith, Alexandra O Sokolova, et al.Clinical Genitourinary Cancer|February 21, 2012
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancerMark T Fleming, Guru Sonpavde, Michael Kolodziej, et al.Cancer Prevention Research (Philadelphia, Pa.)|May 5, 2024
Outcomes following a false positive multi-cancer early detection (MCED) test: Results from DETECT-A, the first large, prospective, interventional MCED studyAnne Marie Lennon, Adam H Buchanan, Seema P Rego, et al.Cancer Prevention Research (Philadelphia, Pa.)|June 10, 2024
Outcomes Following a False-Positive Multi-Cancer Early Detection Test: Results from DETECT-A, the First Large, Prospective, Interventional MCED StudyAnne M Lennon, Adam H Buchanan, Seema P Rego, et al.Pageof 28